KalVista Pharmaceuticals, Inc. (KALV)
16.90
-0.02
(-0.09%)
USD |
NASDAQ |
Dec 15, 16:00
16.90
0.00 (0.00%)
After-Hours: 19:03
KalVista Pharmaceuticals Research and Development Expense (TTM): 55.64M for Sept. 30, 2025
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| BioCryst Pharmaceuticals, Inc. | 173.40M |
| Iovance Biotherapeutics, Inc. | 303.64M |
| Travere Therapeutics, Inc. | 210.21M |
| Xenetic Biosciences, Inc. | 2.630M |
| BeyondSpring, Inc. | -- |